Pierre Fabre Pharma GmbH secures contract for Pharmaceutical products - conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient propranolol (exclusively LSE), ATC C07AA05 for the period 01072024 - 30062026

Germany, July 6 -- Germany based Pierre Fabre Pharma GmbH has secured contract from DAK-Gesundheit for Pharmaceutical products - conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient propranolol (exclusively LSE), ATC C07AA05 for the period 01072024 - 30062026 . The value of the contract is not disclosed .

Published by HT Digital Content Services with permission from Pivotal Sources....